10-Q: OS Therapies Reports First Quarter 2024 Financial Results, Cites Ongoing Clinical Trial and Funding Efforts

OS Therapies Incorporated reported a net loss of $1.49 million for the first quarter of 2024, while continuing to advance its Osteosarcoma therapy and seek additional capital.

Summary

• OS Therapies Incorporated, a clinical-stage biopharmaceutical company, released its financial results for the quarter ended March 31, 2024.
• The company reported a net loss of $1.49 million, compared to a net loss of $1.88 million for the same period in 2023.
• Research and development expenses decreased to $361,809 from $753,784 year-over-year, primarily due to reduced vendor expenses related to the Phase IIb clinical trial and the OST-tADC platform.
• General and administrative expenses remained relatively stable at $268,423 compared to $294,247 in the prior year.
• Interest expense was $828,760, similar to the $798,938 reported in the first quarter of 2023.
• The company's cash balance was $100,231 as of March 31, 2024, up from $38,982 at the end of 2023.
• OS Therapies is actively seeking additional capital through public or private financing to continue operations.
• The company has an ongoing clinical trial for Osteosarcoma therapy and is developing a next-generation antibody-drug conjugate (ADC) technology.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive aspects, such as reduced R&D expenses and a slightly improved net loss compared to the previous year, the company's financial position is precarious due to its low cash balance, significant accumulated deficit, and dependence on additional funding. The ongoing arbitration and ineffective disclosure controls also contribute to a negative sentiment.

Positives

• The net loss decreased year-over-year, indicating improved financial performance.
• Research and development expenses were significantly reduced, potentially reflecting cost management.
• The company's cash balance increased, providing some short-term financial flexibility.
• The company is actively pursuing additional funding, which could support future growth.
• The company is progressing with its clinical trial for Osteosarcoma therapy.
• The development of the OST-tADC platform could provide future growth opportunities.

Negatives

• The company continues to operate at a loss, with a net loss of $1.49 million for the quarter.
• The company has a significant accumulated deficit of $31.0 million.
• The company's ability to continue operations is dependent on securing additional capital.
• The company has a substantial amount of convertible debt, which could dilute existing shareholders upon conversion.
• The company's disclosure controls and procedures are not effective due to a lack of segregation of duties and insufficient written policies.
• The company is involved in an arbitration proceeding with Noble Capital Markets, which could result in the issuance of additional shares.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional capital.
• The company has incurred net losses since its inception and has negative operating cash flows.
• There is no assurance that the company will be successful in raising additional capital.
• The company's convertible debt could dilute existing shareholders upon conversion.
• The company's disclosure controls and procedures are not effective, which could lead to errors in financial reporting.
• The company is involved in an arbitration proceeding with Noble Capital Markets, which could result in the issuance of additional shares and legal expenses.
• The company is subject to risks associated with clinical trials and regulatory approvals.

Future Outlook

The company expects to incur significant expenses at an increasing rate and increasing operating losses for the foreseeable future. The company is seeking to develop, manufacture and commercialize multiple product candidates targeting orphan and non-orphan oncologic diseases. They are also considering out-licensing OST-HER2 to animal health companies and obtaining marketing approval for OST-HER2 in Osteosarcoma, then expanding to other solid tumors. They also plan to conclude pre-clinical and toxicology trials with the lead drug candidate for OST-tADC and file for an investigational new drug application (IND).

Management Comments

• The company's mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
• The company is seeking to develop, manufacture and commercialize multiple product candidates targeting orphan and non-orphan oncologic diseases across multiple tissue types and therapeutic areas.
• The company believes that there have not been any new treatments approved by the U.S. Food and Drug Administration (FDA) for Osteosarcoma for more than 40 years.

Industry Context

The company operates in the biopharmaceutical industry, focusing on developing treatments for Osteosarcoma and other solid tumors. The document highlights the unmet need for new treatments in Osteosarcoma, a rare cancer primarily affecting children and young adults. The company's focus on immunotherapy and antibody-drug conjugate technologies aligns with current trends in cancer treatment. The company is also exploring out-licensing opportunities in the animal health sector, which is a growing area of interest for biopharmaceutical companies.

Comparison to Industry Standards

• OS Therapies is a clinical-stage company, and its financial results are typical for companies at this stage, characterized by significant research and development expenses and net losses.
• The company's focus on Osteosarcoma, a rare cancer, is a niche area compared to larger pharmaceutical companies that focus on more prevalent cancers.
• The company's development of a tunable ADC platform is a novel approach, and its success will depend on the results of preclinical and clinical trials.
• Compared to companies like Ayala Pharmaceuticals (formerly Advaxis), with whom they have a licensing agreement, OS Therapies is at an earlier stage of development.
• The company's reliance on convertible debt financing is common for early-stage biotech companies, but it also carries the risk of dilution for existing shareholders.
• The company's cash balance of $100,231 is low compared to industry standards for companies with ongoing clinical trials, highlighting the need for additional funding.

Management Changes

Corporate Governance

Legal Proceedings

• On April 12, 2024, Noble Capital Markets, Inc. filed a Demand for Arbitration against OS Therapies, claiming a breach of the anti-dilution provision in the parties advisory agreement.
• The company will reserve for issuance 474,134 shares of common stock until final disposition of the arbitration.
• A hearing on Noble's request for preliminary injunctive relief is scheduled for June 7, 2024.

Related Party Transactions

• The company had a payroll payable to the CEO of $330,000 and $300,000 as of March 31, 2024 and December 31, 2023, respectively.
• 8.67% of Group A and 4.55% of Group E convertible notes are held by related parties.
• The company has a bill in accounts payable of $58,100 for the period ended March 31, 2024 to Shore Accountants MD Inc., an outside accounting firm 100% owned by the company's CFO.

Stakeholder Impact

• Shareholders face the risk of dilution due to the company's convertible debt and potential issuance of additional shares in the arbitration proceeding.
• Employees may be impacted by the company's financial instability and dependence on additional funding.
• Customers (patients) may benefit from the company's development of new cancer treatments, but the success of these treatments is not guaranteed.
• Suppliers and creditors may be at risk due to the company's financial instability and dependence on additional funding.
• The company's ongoing clinical trial and development of new technologies could have a positive impact on the medical community.

Next Steps

• The company intends to obtain marketing approval for OST-HER2 in Osteosarcoma.
• The company plans to expand its pipeline beyond Osteosarcoma into other solid tumors.
• The company will conclude pre-clinical and toxicology trials with the lead drug candidate for OST-tADC.
• The company will file for an investigational new drug application (IND) to initiate a Phase I trial in ovarian cancer.
• The company will establish global commercial and medical affairs capabilities for OST-HER2 based therapies.

Key Dates

Keywords

Osteosarcoma, Immunotherapy, Antibody-drug conjugate, Clinical trial, Biopharmaceutical, Convertible debt, Financial results, Net loss, Research and development, Capital raise